Phase III, open-label, randomized, multicenter study of injectable liposomal irinotecan, oxaliplatin, 5-fluorouracil / leucovorin versus nabpaclitaxel plus gemcitabine in patients who have not previously received chemotherapy for adenocarcin
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: IPSEN BIOSCIENCE, INC.
- Phase: III
- Execution start: 18/03/2020
- End of execution: 30/05/2022
- PI: JOAQUINA MARTINEZ GALAN